Xin Lang Cai Jing·2025-09-04 03:31Group 1 - The core viewpoint of the news is that Nocera Biopharma experienced a decline in stock price, dropping by 5.04% to 28.08 CNY per share, with a trading volume of 1.67 billion CNY and a turnover rate of 2.14%, resulting in a total market capitalization of 495.51 billion CNY [1] - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Group 2 - From the perspective of major fund holdings, a fund under Yinhua Asset Management holds a significant position in Nocera Biopharma, with 267,100 shares representing 5.11% of the fund's net value, ranking as the seventh-largest holding [2] - The Yinhua CSI All-Share Healthcare Index Enhanced Fund (005112) has a total scale of 1.28 billion CNY and has achieved a year-to-date return of 31.97%, ranking 1002 out of 4222 in its category [2] - The fund has a one-year return of 47.33%, ranking 1796 out of 3789, and a cumulative return since inception of 57.47% [2]